Healthcare company Novo Nordisk has settled a lawsuit against Pfizer claiming that Pfizer's product Exubera infringed patents owned by Novo Nordisk.
Subscribe to our email newsletter
The patents cover inhaled insulin treatment for diabetes. Detailed terms of the settlement were not disclosed.
The lawsuit was originally filed in August 2006 in US Federal Court in the Southern District of New York. In December 2006, a federal judge in Manhattan denied a request by Novo Nordisk to halt Exubera sales, saying the need for new treatments trumped Novo’s allegations of patent infringement.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.